EU Green Lights Apalutamide for Nonmetastatic CRPC EU Green Lights Apalutamide for Nonmetastatic CRPC

The next-generation antiandrogen has received a positive opinion for nonmetatatic castration-resistant prostate cancer (CRPC), considered to be an unmet medical need.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news